These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 11131957

  • 1. The use of levofloxacin in the treatment of respiratory tract infection.
    Shah PM.
    J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
    [Abstract] [Full Text] [Related]

  • 2. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
    Casellas JM, Gilardoni M, Tome G, Goldberg M, Ivanovic S, Orduna M, Dolmann A, Ascoli M, Ariza H, Montero JM.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [Abstract] [Full Text] [Related]

  • 6. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA, Ehrhardt AF, Jones RN.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [Abstract] [Full Text] [Related]

  • 7. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV, Iakovlev VP.
    Antibiot Khimioter; 2002 Dec 17; 47(8):32-42. PubMed ID: 12515095
    [No Abstract] [Full Text] [Related]

  • 8. Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
    Blasi F.
    J Chemother; 2004 Apr 17; 16 Suppl 2():11-4. PubMed ID: 15255556
    [No Abstract] [Full Text] [Related]

  • 9. Levofloxacin in the treatment of community acquired pneumonia.
    File TM.
    Can Respir J; 1999 Apr 17; 6 Suppl A():35A-9A. PubMed ID: 10202232
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ, Jung R, Garvin CG.
    Drug Saf; 2001 Apr 17; 24(3):199-222. PubMed ID: 11347723
    [Abstract] [Full Text] [Related]

  • 13. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A, Ishii Y, Kobayashi I, Yamaguchi K.
    J Infect Chemother; 2007 Oct 17; 13(5):296-301. PubMed ID: 17982717
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].
    Bogdanov MB, Chernen'kaia TV.
    Antibiot Khimioter; 2000 Oct 17; 45(10):15-8. PubMed ID: 11212394
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
    Davies BI, Maesen FP.
    J Antimicrob Chemother; 1999 Jun 17; 43 Suppl C():83-90. PubMed ID: 10404344
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H, Liu YL, Chen MJ, Xu YC, Sun HL, Yang QW, Hu YJ, Cao B, Chu YZ, Liu Y, Zhang R, Yu YS, Sun ZY, Zhuo C, Ni YX, Hu BJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb 17; 35(2):113-9. PubMed ID: 22455967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.